Biohit

Biohit Oyj is a Finnish biotechnology and diagnostics company established in 1988 by Professor Osmo Suovaniemi, M.D., Ph.D., who had previously founded Labsystems. The company develops, manufactures, and markets products for laboratory research and healthcare, with activities centered on diagnostic testing, acetaldehyde-eliminating products, monoclonal antibodies, and laboratory instruments and liquid-handling systems. Biohit’s healthcare portfolio is particularly associated with GastroPanel, a blood-based examination intended to help assess Helicobacter pylori infection and atrophic gastritis. The test is also positioned as an aid in identifying people who may have elevated risks associated with gastric cancer, peptic ulcer disease, gastroesophageal reflux disease, and deficiencies involving vitamin B12, calcium, and iron. Alongside GastroPanel, the company offers rapid tests covering areas such as lactose intolerance, H. pylori infection, celiac disease, and colorectal-cancer screening. A second business area focuses on acetaldehyde-binding products. Biohit developed products intended to reduce exposure to acetaldehyde in the mouth and digestive tract, and in 2018 introduced Acetium Lozenge, a nicotine-free product marketed for smoking cessation. The company also develops and manufactures monoclonal antibodies for research applications and as raw materials used by the diagnostics industry. Biohit’s laboratory business complements its diagnostic tests. Its offering includes microplate instruments, automation, and liquid-handling products designed to support laboratory workflows and Biohit ELISA testing. This systems-oriented approach links consumables, instruments, and diagnostic methods rather than limiting the company to a single test category. The company operates internationally. It has subsidiaries in Italy and the United Kingdom and uses a distributor network of approximately 40 distributors across more than 40 countries. The United States distribution arrangement identified in the reference material is handled by Bio Testing Supplies, a division of Avrio Genetics. More than 90 percent of Biohit’s sales occur outside Finland, underscoring the company’s export-oriented business model. Research and intellectual property are central to Biohit’s positioning. The company has reported allocating roughly 30 percent of net sales to basic research and pursuing an active patenting strategy. Its brand therefore combines clinical diagnostics, laboratory technology, and product development based on proprietary scientific work. Osmo Suovaniemi left the chief executive role in June 2011 but continued to participate through advisory-board positions. Semi Korpela was appointed chief executive in 2011. Biohit’s Series B shares have been quoted on the Helsinki exchange since 1999 in the small-cap healthcare segment.

Biohit was established in Finland in 1988 by Professor Osmo Suovaniemi, M.D., Ph.D. Suovaniemi had previously been associated with the founding of Labsystems, giving Biohit an origin rooted in laboratory technology and biomedical entrepreneurship. From its beginning, the company pursued a combination of scientific research, product development, manufacturing, and commercial distribution rather than operating solely as a contract research organization or a single-product diagnostics business. The company’s subsequent development brought together two related operating areas: acetaldehyde-eliminating products and diagnostics. The diagnostic side expanded around tests intended for clinical assessment and screening. Its GastroPanel examination uses a blood sample to aid assessment of Helicobacter pylori infection and atrophic gastritis. The test is also presented as a tool for identifying people who may warrant attention because of risks associated with gastric cancer, peptic ulcer disease, gastroesophageal reflux disease, and selected nutrient deficiencies. Biohit’s broader rapid-test range covers lactose intolerance, H. pylori infection, celiac disease, and colorectal-cancer screening. Biohit also built capabilities in laboratory research products. The company develops and manufactures monoclonal antibodies for research use and for use as raw materials by the diagnostics industry. Its instruments and laboratory systems include microplate equipment, automation, and liquid-handling products. These offerings support ELISA testing and other laboratory processes, giving Biohit a business model that combines diagnostic reagents and tests with equipment used in sample and assay workflows. A major structural milestone came in 1999, when the company’s Series B shares began quotation on NASDAQ OMX Helsinki. The shares were associated with the exchange’s small-cap healthcare segment. Public-market status supported Biohit’s identity as an independent Finnish healthcare and biotechnology company, while its commercial model remained strongly international. The company established subsidiaries in Italy and the United Kingdom and developed a distributor network of about 40 distributors covering more than 40 countries. The reference material states that over 90 percent of sales took place outside Finland. Leadership changed in 2011. Suovaniemi stepped down as chief executive in June of that year, although he remained involved with Biohit through positions on advisory boards. Semi Korpela was appointed chief executive in 2011. This transition separated the company’s continuing founder influence from day-to-day executive management while retaining access to Suovaniemi’s scientific and strategic experience. Biohit’s product development later extended its acetaldehyde-binding business into smoking cessation. In 2018, it launched Acetium Lozenge, described as a nicotine-free smoking-cessation product. The launch broadened the practical application of the company’s acetaldehyde-related technology beyond laboratory and diagnostic contexts. Research, development, and intellectual property have remained important to Biohit’s corporate identity. The company has reported spending approximately 30 percent of net sales on basic research and maintaining an active patenting strategy. This emphasis supports a positioning based on proprietary biomedical technology rather than commodity laboratory distribution. Overall, Biohit’s history is that of a Finnish, export-oriented biotechnology company combining clinical diagnostics, laboratory systems, antibodies, and acetaldehyde-binding products, with commercial reach supplied by subsidiaries and international distributors.

• 2018

  Acetium Lozenge introduced

  [1]Biohiten.wikipedia.org

  Biohit launched a nicotine-free smoking-cessation product in its acetaldehyde-binding product category.

• 2011

  Founder leaves chief executive role

  [1]Biohiten.wikipedia.org

  Osmo Suovaniemi stepped down as CEO in June, while Semi Korpela was appointed CEO during the same year.

• 1999

  Series B shares quoted in Helsinki

  [1]Biohiten.wikipedia.org

  Biohit’s Series B shares began quotation on NASDAQ OMX Helsinki in the small-cap healthcare segment.

• 1988

  Biohit founded in Finland

  [1]Biohiten.wikipedia.org

  Professor Osmo Suovaniemi established Biohit as a Finnish biotechnology company serving research and healthcare applications.

A research-driven Finnish biotechnology company combining in-vitro diagnostics, preventive healthcare testing, acetaldehyde-eliminating products, antibodies, and laboratory workflow equipment for international research and healthcare markets.

• Diagnostic examination

  GastroPanel

  GastroPanel is a blood-based diagnostic examination used to aid assessment of Helicobacter pylori infection and atrophic gastritis. The examination is also positioned as a way to identify people at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease, and deficiencies involving vitamin B12, calcium, and iron.

• Rapid diagnostics

  Biohit Quick Tests

  Biohit’s quick-test range covers several screening and detection applications, including lactose intolerance, Helicobacter pylori infection, celiac disease, and colorectal cancer. The tests extend the company’s diagnostic portfolio beyond the GastroPanel examination and are intended for use in healthcare testing contexts.

• Smoking-cessation product · 2018

  Acetium Lozenge

  Acetium Lozenge is a nicotine-free product introduced in 2018 as part of Biohit’s acetaldehyde-binding business. It is associated with the company’s effort to apply acetaldehyde-eliminating technology to smoking cessation rather than relying on nicotine replacement.

• Research and diagnostic raw materials

  Monoclonal antibodies

  Biohit develops and manufactures monoclonal antibodies for research use and for use as raw materials in the diagnostic industry. This activity supports both laboratory research customers and the wider development and production of diagnostic assays.

• Laboratory equipment

  Laboratory instruments and liquid-handling products

  Biohit supplies microplate instruments, laboratory automation, and liquid-handling products. These systems support laboratory workflows and Biohit ELISA tests, linking the company’s instruments and consumables with its diagnostic and research activities.

• 2018

  Expansion into nicotine-free smoking cessationProduct launch

  Background

  Biohit’s business included products designed to bind or eliminate acetaldehyde, alongside diagnostics and laboratory technology.

  Action taken

  The company launched Acetium Lozenge, a nicotine-free smoking-cessation product.

  Aftermath

  The launch broadened the commercial application of Biohit’s acetaldehyde-related product technology.

  Source

• 2011

  Leadership transition from founder managementStrategy

  Background

  Biohit had been founded and led by Osmo Suovaniemi, who had a prior history in Finnish laboratory technology entrepreneurship.

  Action taken

  Suovaniemi stepped down as CEO in June 2011, and Semi Korpela was appointed CEO during the year; Suovaniemi continued involvement through advisory boards.

  Aftermath

  The company retained founder participation in an advisory capacity while moving day-to-day executive leadership to Korpela.

  Source

1. 1Biohiten.wikipedia.org